Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN E LEWIS

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1871773705
CMS profile
1185195
Location
NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$315.41

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $315.41 13

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Astellas Pharma US Inc $86.96 4
Merck Sharp & Dohme LLC $50.42 1
Gilead Sciences, Inc. $50.25 2
Celgene Corporation $32.17 2
Daiichi Sankyo Inc. $27.86 1
RECORDATI_RARE_DISEASES_INC. $25.52 1
Eisai Inc. $24.77 1
Tempus AI, Inc $17.46 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN E LEWIS

NPI 1871773705 · CMS profile ID 1185195

Allopathic & Osteopathic Physicians / Internal Medicine

NEW ORLEANS, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRIAN E LEWIS, NPI 1871773705, CMS profile ID 1185195, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1871773705?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $315.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $26.8411/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133763064 CMS
Merck Sharp & Dohme LLC $50.4211/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141686325 CMS
Astellas Pharma US Inc $13.9011/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139445248 CMS
Celgene Corporation $15.6911/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101116280 CMS
Celgene Corporation $16.4811/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101116278 CMS
Astellas Pharma US Inc $26.9008/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139347242 CMS
Tempus AI, Inc $17.4606/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150168516 CMS
RECORDATI_RARE_DISEASES_INC. $25.5206/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139164256 CMS
Gilead Sciences, Inc. $23.4105/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133763062 CMS
Astellas Pharma US Inc $29.5704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139354975 CMS
Astellas Pharma US Inc $16.5904/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139324030 CMS
Daiichi Sankyo Inc. $27.8601/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089448692 CMS
Eisai Inc. $24.7701/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $66.66 4
PY2020 $66.69 3
PY2021 $99.95 1
PY2022 $20.02 1
PY2023 $169.24 8
PY2024 $315.41 13
PY2025 $261.75 11

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $333,143.56 79
PY2024 Recipient $1,993.89 3
PY2024 Principal investigator $405,724.59 16
PY2023 Principal investigator $899,284.11 32
PY2022 Principal investigator $114,917.88 36
PY2021 Principal investigator $13,252.00 2
PY2020 Principal investigator $142,805.58 3
PY2019 Principal investigator $60,217.32 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $22,150.54 12/31/2025 Non-covered Recipient Entity
Tulane University School of Medicine
A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Participants who are Cisplatin-Ineligible or Decline Cisplatin with Muscle- No dispute reported 06/30/2026 1232927749
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910985
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910987
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910989
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911007
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911019
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911021
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911023
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,410.45 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911025
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911027
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,045.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911029
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911047
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,500.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911049
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911051
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,500.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911053
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,500.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911055
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911057
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911059
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911061
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,300.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911063
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,536.00 12/19/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911105
Principal investigator 1 Novartis Pharmaceuticals Corporation $54.90 12/17/2025 Non-covered Recipient Entity
TULANE UNIVERSITY HEALTH SCIENCES CENTER
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190303047
Principal investigator 1 PFIZER INC. $820.00 12/15/2025 Non-covered Recipient Entity
TULANE CANCER CENTER
A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228751504
Principal investigator 1 PFIZER INC. $820.00 11/24/2025 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228723792
Principal investigator 1 Novartis Pharmaceuticals Corporation $343.03 11/15/2025 Non-covered Recipient Entity
TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190306995
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910991
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910993
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910995
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910997
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199910999
Principal investigator 1 Aveo Pharmaceuticals, Inc. $300.38 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911001
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.17 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911003
Principal investigator 1 Aveo Pharmaceuticals, Inc. $410.94 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911005
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911009
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911011
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911013
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.17 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911015
Principal investigator 1 Aveo Pharmaceuticals, Inc. $301.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911017
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911031
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911033
Principal investigator 1 Aveo Pharmaceuticals, Inc. $301.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911035
Principal investigator 1 Aveo Pharmaceuticals, Inc. $157.82 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911037
Principal investigator 1 Aveo Pharmaceuticals, Inc. $300.38 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911039
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911041
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911043
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911045
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911065
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911067
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911069
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911071
Principal investigator 1 Aveo Pharmaceuticals, Inc. $217.89 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911073
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911075
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.17 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911077
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.17 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911079
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911081
Principal investigator 1 Aveo Pharmaceuticals, Inc. $157.82 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911083
Principal investigator 1 Aveo Pharmaceuticals, Inc. $410.94 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911085
Principal investigator 1 Aveo Pharmaceuticals, Inc. $301.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911087
Principal investigator 1 Aveo Pharmaceuticals, Inc. $13.17 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911089
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911091
Principal investigator 1 Aveo Pharmaceuticals, Inc. $157.82 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911093
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911095
Principal investigator 1 Aveo Pharmaceuticals, Inc. $410.94 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911097
Principal investigator 1 Aveo Pharmaceuticals, Inc. $246.78 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911099
Principal investigator 1 Aveo Pharmaceuticals, Inc. $217.89 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911101
Principal investigator 1 Aveo Pharmaceuticals, Inc. $284.18 10/30/2025 Non-covered Recipient Entity
Tulane University
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1199911103
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,232.50 10/02/2025 Non-covered Recipient Entity
TULANE UNIVERSITY SCHOOL OF MEDICINE
A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer No dispute reported 06/30/2026 1185549545
Principal investigator 1 PFIZER INC. $3,000.00 07/28/2025 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228758689
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $684.00 07/22/2025 Non-covered Recipient Entity
Tulane University
A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma No dispute reported 06/30/2026 1235992853
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,250.00 07/18/2025 Non-covered Recipient Entity
TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate Cancer No dispute reported 06/30/2026 1190312253
Principal investigator 1 Janssen Research & Development, LLC $114.00 06/06/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE ED UCATIONAL FUND DBA TULANE UNIVERSIT
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175400416
Principal investigator 1 Janssen Research & Development, LLC $2,250.00 06/02/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE ED UCATIONAL FUND DBA TULANE UNIVERSIT
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175400411
Principal investigator 1 PFIZER INC. $820.00 06/02/2025 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCAT
A STUDY OF ENFORTUMAB VEDOTIN ASG22CE AS MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES FOR THE TREATMENT OF UROTHELIAL CANCER No dispute reported 06/30/2026 1228792493
Recipient PFIZER INC. $940.00 05/31/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228753677
Principal investigator 1 Janssen Research & Development, LLC $340.00 03/07/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE ED UCATIONAL FUND DBA TULANE UNIVERSIT
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175400386
Principal investigator 1 Eli Lilly and Company $3,805.65 02/06/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187892144
Principal investigator 1 Janssen Research & Development, LLC $2,701.00 02/03/2025 Non-covered Recipient Entity
THE ADMINISTRATORS OF THE TULANE ED UCATIONAL FUND DBA TULANE UNIVERSIT
A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer No dispute reported 06/30/2026 1175400391
Recipient PFIZER INC. $330.00 01/28/2025 Covered Recipient Physician ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228770990
Principal investigator 1 Novartis Pharmaceuticals Corporation $70,361.67 01/21/2025 Non-covered Recipient Entity
ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190311593
Principal investigator 1 Novartis Pharmaceuticals Corporation $205.08 01/15/2025 Non-covered Recipient Entity
TULANE UNIVERSITY HEALTH SCIENCES CENTER
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1190303049
Principal investigator 1 Novartis Pharmaceuticals Corporation $137,668.19 01/15/2025 Non-covered Recipient Entity
TULANE CANCER CENTER OFFICE OF CLINICAL RESEARCH
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190312255